These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 21364521)

  • 21. Another case of reversibility of visual-field defect induced by vigabatrin monotherapy: is young age a favorable factor?
    Giordano L; Valseriati D; Vignoli A; Morescalchi F; Gandolfo E
    Neurol Sci; 2000 Jun; 21(3):185-6. PubMed ID: 11076009
    [No Abstract]   [Full Text] [Related]  

  • 22. Visual field defect associated with vigabatrin. Method of estimating prevalence was inappropriate.
    Manuchehri K
    BMJ; 2000 May; 320(7246):1403-4; author reply 1404. PubMed ID: 10858055
    [No Abstract]   [Full Text] [Related]  

  • 23. Visual field defect associated with vigabatrin: observational cohort study.
    Wilton LV; Stephens MD; Mann RD
    BMJ; 1999 Oct; 319(7218):1165-6. PubMed ID: 10541505
    [No Abstract]   [Full Text] [Related]  

  • 24. Vigabatrin-associated loss of vision: rarebit perimetry illuminates the dose-damage relationship.
    Frisén L
    Acta Ophthalmol Scand; 2004 Feb; 82(1):54-8. PubMed ID: 14738486
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Visual field defect associated with vigabatrin. Means of selecting patients was misleading.
    Midelfart A
    BMJ; 2000 May; 320(7246):1404. PubMed ID: 10858056
    [No Abstract]   [Full Text] [Related]  

  • 26. Visual field loss in young children and mentally handicapped adolescents receiving vigabatrin.
    Werth R; Schädler G
    Invest Ophthalmol Vis Sci; 2006 Jul; 47(7):3028-35. PubMed ID: 16799049
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Progressive vigabatrin-associated visual field loss and the importance of continuing assessment of risks and benefit of epilepsy treatments.
    Treiman DM
    Epilepsy Res; 2013 Aug; 105(3):261. PubMed ID: 23830726
    [No Abstract]   [Full Text] [Related]  

  • 28. The natural history of Vigabatrin-associated visual field defects in patients electing to continue their medication.
    Kumar N; Jivan S
    Eye (Lond); 2006 Sep; 20(9):1082-3; author reply 1083-4. PubMed ID: 16244645
    [No Abstract]   [Full Text] [Related]  

  • 29. Vigabatrin-induced visual dysfunction in Chinese patients with refractory epilepsy.
    Hui AC; Liu DT; Wong KK; Man BL; Leung T; Lam PT; Lam DS
    Eur J Ophthalmol; 2008; 18(4):624-7. PubMed ID: 18609486
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Characteristics of a unique visual field defect attributed to vigabatrin.
    Wild JM; Martinez C; Reinshagen G; Harding GF
    Epilepsia; 1999 Dec; 40(12):1784-94. PubMed ID: 10612345
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Vigabatrin-associated visual field defects in children.
    Russell-Eggitt IM; Mackey DA; Taylor DS; Timms C; Walker JW
    Eye (Lond); 2000 Jun; 14 ( Pt 3A)():334-9. PubMed ID: 11026995
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Visual field loss associated with vigabatrin: quantification and relation to dosage.
    Hardus P; Verduin WM; Engelsman M; Edelbroek PM; Segers JP; Berendschot TT; Stilma JS
    Epilepsia; 2001 Feb; 42(2):262-7. PubMed ID: 11240600
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Visual field defects in patients taking vigabatrin.
    Midelfart A; Midelfart E; Brodtkorb E
    Acta Ophthalmol Scand; 2000 Oct; 78(5):580-4. PubMed ID: 11037919
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Vigabatrin-associated visual field constriction in a longitudinal series. Reversibility suggested after drug withdrawal.
    Fledelius HC
    Acta Ophthalmol Scand; 2003 Feb; 81(1):41-6. PubMed ID: 12631018
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Measuring field loss in children administered vigabatrin: a problem in search of a solution.
    Good WV
    J AAPOS; 2011 Oct; 15(5):411-2. PubMed ID: 22108349
    [No Abstract]   [Full Text] [Related]  

  • 36. Screening of patients taking vigabatrin.
    Rebolleda G; Muñoz-Negrete FJ; Gutierrez C
    Ophthalmology; 2000 Jul; 107(7):1219-20. PubMed ID: 10889083
    [No Abstract]   [Full Text] [Related]  

  • 37. Full-field ERG and visual fields in patients 5 years after discontinuing vigabatrin therapy.
    Kjellström U; Lövestam-Adrian M; Andréasson S; Ponjavic V
    Doc Ophthalmol; 2008 Sep; 117(2):93-101. PubMed ID: 18188629
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A controlled study of vigabatrin and visual abnormalities.
    Manuchehri K; Goodman S; Siviter L; Nightingale S
    Br J Ophthalmol; 2000 May; 84(5):499-505. PubMed ID: 10781514
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Objective Derivation of the Morphology and Staging of Visual Field Loss Associated with Long-Term Vigabatrin Therapy.
    Wild JM; Smith PEM; Knupp C
    CNS Drugs; 2019 Aug; 33(8):817-829. PubMed ID: 31250314
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Visual field severity indices demonstrate dose-dependent visual loss from vigabatrin therapy.
    Conway M; Cubbidge RP; Hosking SL
    Epilepsia; 2008 Jan; 49(1):108-16. PubMed ID: 18184224
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.